Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: Toward a treatment approach

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 7, 1996, Pages 55-63

  Mintzer, Jacobo E ^a   Brawman Mintzer, Olga ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGITATION; ANXIETY NEUROSIS; ARTICLE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; PRIORITY JOURNAL;

AGED; AGGRESSION; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BEHAVIOR THERAPY; BUSPIRONE; CARBAMAZEPINE; CLOZAPINE; COMBINED MODALITY THERAPY; DECISION TREES; DEMENTIA; HUMANS; ONDANSETRON; PSYCHOMOTOR AGITATION; SEROTONIN; TRAZODONE;

EID: 0029763295     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994;151:640-649
2. Copeland JRM, Dewey ME, Wood N, et al. Range of mental illness among the elderly in the community: prevalence in Liverpool using the GMS-AGECAT package. Br J Psychiatry 1987;150:815-823
3. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly, I: a conceptual review. J Am Geriatr Soc 1986;34:711-721
4. Cohen-Mansfield J. Agitated behaviors in the elderly, II: preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986;34:722-727
5. Eisdorfer C, Cohen D, Paveza GJ, et al. An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's disease. Am J Psychiatry 1992;149:190-194
6. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist 1986;26:260-266
7. Cohen-Mansfield J, Marx M, Werner P. Agitation in elderly persons: an integrative report of findings in a nursing home. Int Psychogeriatr 1992;4:221-240
8. Ryden MB. Aggressive behaviors in persons with dementia who live in the community. Alzheimer Dis Assoc Disord 1988;2:342-355
9. Teri L, Larson EB, Reifler BV. Behavioral disturbances in dementia of the Alzheimer's type. J Am Geriatr Soc 1988;36:1-6
10. Wild K, Aronson M, Yatzkan E. Agitation in Alzheimer's disease: description and measurement. Gerontologist 1987;27(Oct, special issue):225-A
11. Brody EM, Kleban MH, Lawton P, et al. Excess disabilities of mentally impaired aged: impact of individualized treatment. Gerontologist 1971;11:124-133
12. Goldstein K. The effect of brain damage on the personality. Psychiatry 1952;15:245-260
13. Roper JM, Shapira J, Chang BL. Agitation in the demented patient: a framework for management. Journal of Gerontological Nursing 1991;17:17-20
14. Gilley DW, Wilson RS, Bennett DA, et al. Predictors of behavioral disturbance in Alzheimer's disease. J Gerontol 1991;46:362-371
15. Jarvick LF, Wiseman EJ. A check list for managing the dementia patient. Geriatrics 1991;46:31-34, 39-40
16. Teri L, Logsdon R. Assessment and management of behavioral disturbances in Alzheimer's disease. Compr Ther 1990;16:36-42
17. Mintzer JE, Lewis L, Pennypacker L, et al. Behavioral Intensive Care Unit (BICU): a new concept in the management of acute agitated behavior in elderly demented patients. Gerontologist 1993;33:801-806
18. Caplette CL, Pitner JK, Mintzer JE. Evaluation of psychoactive drug therapy in community-dwelling elderly demented patients. Journal of Geriatric Drug Therapy 1995;2(9)
19. Yen CY, Stangler RL, Millman N. Ataractic suppression of isolation-induced aggressive behavior. Archives of International Pharmacodynamics 1959;123:179-185
20. Kantak KM, Hegstrand LR, Eichelman B. Facilitation of shock-induced fighting following intraventricular 5,7-dihydroxy-typtamine and 6-hydroxydopa. Psychopharmacology (Berl) 1981;74:157-160
21. Asberg M, Schalling D, Traskmann-Bendz L, et al. Psychobiology of suicide, impulsivity, and related phenomena. In: Meltzer HY, ed. Psychopharmacology: Third Generation of Progress. New York, NY: Raven Press; 1987:655-688
22. Brown GL, Goodwin FK, Ballenger JC, et al. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1979;1:131-139
23. Brown GL, Ebert MH, Goyer PF, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Psychiatry Res 1982; 139:741-746
24. Van Praag HM. Auto aggression and CSF 5-HIAA in depression and schizophrenia. Psychopharmacol Bull 1986;22:669-673
25. Roy-Byrne P, Post RM, Rubinow DR, et al. CSF 5-HIAA and personal and family history of suicide in affectively ill patients: a negative study. Psychiatry Res 1983;10:263-274
26. Traskman L, Asberg M, Bertilsson L, et al. Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981;38:631-636
27. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 1976;33:1193-1197
28. Brown GL, Goodwin FK. Diagnostic, clinical and personality characteristics of aggressive men with low 5-HIAA. Clin Neuropharmacol 1984; 7(suppl):S408-S409
29. Cooper SJ, Kelly CB, King DJ. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. Lancet 1992;340:940-941
30. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-599
31. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry 1989;155(suppl 8):52-62
32. Gottfries CG, Gottfries I, Roos BE. Homovanillic acid and 5-hydroxy indoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia, and parkinsonism. J Neurochem 1969;16: 1341-1345
33. Soininen H, MacDonald E, Rekonen M, et al. Homovanillic acid and 5-hydroxy indoleacetic acid levels in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Acta Neurol Scand 1981;64:101-107
34. Smith CC, Bowen DM, Sims NR, et al. Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer's disease. Brain Res 1983;264:138-141
35. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990;157:894-901
36. Gottfries CG, Nyth AL. Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N Y Acad Sci 1991;640:276-279
37. Bentham PW. Preliminary communication: a double-blind placebo-controlled trial of L-tryptophan to assess the degree of cognitive and behavioral improvement in patients with Alzheimer-type dementia and to compare differential response in clinical sub-groups. Int Clin Psychopharmacol 1990;5:261-272
38. Sawada M, Hirata Y, Arai H, et al. Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of formal controls and patients with senile dementia of Alzheimer type. J Neurochem 1987;48: 760-764
39. Ridder P. Establishing Alzheimer's disease units in nursing homes: pros and cons. Journal of Neurosurgical Nursing 1985;17:190-200
40. Berg L, Buckwalter KC, Chafetz PK, et al. Special care units for persons with dementia. Am J Geriatr Soc 1991;39:1229-1235
41. Teri L, Borson S, Kiyak HA, et al. Behavioral disturbance, cognitive dysfunction, and functional skill: prevalence and relationship in Alzheimer's disease. J Am Geriatr Soc 1989;37:109-116
42. Teri L, Logsdon R. Assessment and management of behavioral disturbances in Alzheimer's disease. Compr Ther 1990;16:36-42
43. Burgener SC, Jirovec M, Murell L, et al. Caregiver and environmental variables related to difficult behaviors in institutionalized, demented elderly persons. J Gerontol 1992;47:242-247
44. Ryden BM, Feldt KS. Goal-directed care: caring for aggressive nursing home residents with dementia. Journal of Gerontological Nursing 1992; 18:35-42
45. Gold DT, Sloane PD, Mathew LJ, et al. Special care units: a topology of care setting for memory-impaired older adults. Gerontologist 1991; 31:467-475
46. Hall G, Kirshling MV, Todd S. Sheltered freedom: an Alzheimer's unit in an ICF. Geriatric Nursing 1986;7:132-137
47. Johnson CJ. Sociological intervention through development low stimulus Alzheimer's wings in nursing homes. American Journal Alzheimer Care and Related Disorder Research 1989;4:33-41
48. Ackerman JO. Separated not isolated: as basic as administrative backing and commitment. Journal of Long-term Administration 1985;13:90-94
49. Rabins P. Establishing Alzheimer's disease units in nursing homes: pros and cons. Hosp Community Psychiatry 1986;37:120-121
50. Maletta G, Mattow KM, Dysken M. Guidelines for prescribing psychoactive drugs in the elderly: part 1. Geriatrics 1991;46:40-47
51. Goldberg RJ. The use of buspirone in geriatric patients. J Clin Psychiatry Monograph 1994;12(1):31-36
52. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. International Journal of Geriatric Psychiatry 1991;6(10):691-708
53. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. American Journal of Geriatric Psychiatry 1993;1(1): 82-84
54. Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. American Journal of Geriatric Psychiatry 1993;1(3):249-253
55. Cantillon M, Little J, Bahro M, et al. Buspirone vs haloperidol in the treatment of behavioral disturbances in a nursing home population with dementia. American Journal of Geriatric Psychiatry 1995;3(3):251
56. Nair NPV, Ban TA, Hontela S, et al. Trazodone in the treatment of organic brain syndromes, with special reference to psychogeriatrics. Curr Ther Res 1973;15:769-775
57. Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer's disease. J Clin Psychiatry 1994;55:536-538
58. Zoldan J, Friedberg G, Goldberg-Stern H, et al. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993;341(8844):562-563
59. Risse SC, Barnes R. Pharmacologic treatment of agitation associated with dementia. J Am Geriatr Soc 1986;34:368-376
60. Salzman C. Treatment of agitation in the elderly. In: Meltzer HY, ed. Psychopharmacology: Third Generation of Progress. New York, NY: Raven Press; 1987:1167-1176
61. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-563
62. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
63. 2 receptor occupancy during antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:759-767
64. Ereshefsky L, Tran-Johnson TK, Watanabe MD. Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clin Pharm 1990; 9:682-707
65. Alvir JJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
66. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4(2):187-195
67. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56:180-185
68. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. American Journal of Geriatric Psychiatry 1995;3(1):26-33
69. McAllister TW. Carbamazepine in mixed frontal lobe and psychiatric disorders. J Clin Psychiatry 1985;46:393-394
70. Anton RF, Waid LR, Fossey M, et al. Case report of carbamazepine treatment of organic brain syndrome with psychotic features. J Clin Psychopharmacol 1986;6:232-233
71. Essa M. Carbamazepine in dementia. J Clin Psychopharmacol 1986;6: 234-236
72. Leibovici A, Tariot PN. Carbamazepine treatment of agitation associated with dementia. J Geriatr Psychiatry Neurol 1988;1:110-112
73. Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987;28:579-581
74. Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988;1:21-23
75. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry 1990;51: 115-118
76. Chambers CA, Bain J, Rosbottom R, et al. Carbamazepine in senile dementia and overactivity: a placebo controlled double-blind trial. IRCS Medical Science 1982;10:505-506
77. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994;42:1160-1166
78. Mintzer J. Nonpharmacologic treatment of agitation. American Journal of Geriatric Psychiatry 1995;3(3):246-247
79. Brodaty H, Gresman M. Effect of a training program to reduce stress in careers of patients with dementia. BMJ 1989;299:1375-1379